BMY

Business Context and Reporting Period

Company: Bristol-Myers Squibb Company (BMS)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Three and six months ended June 30, 2006
Business Overview: BMS is a global pharmaceutical and health care products company organized into three reportable segments: Pharmaceuticals, Nutritionals, and Other Health Care. The company is currently subject to a Deferred Prosecution Agreement (DPA) with the U.S. Attorney's Office regarding prior accounting matters and is under investigation by the Department of Justice regarding a proposed patent settlement.

Key Financial Metrics

Note: Debt figures represent Short-term borrowings ($189M) plus Long-term debt ($8,239M) as of June 30, 2006.

Material Changes vs. Prior Period

• Revenue: Net sales remained flat for the quarter (-0.4%) but increased 1% for the six-month period. U.S. sales grew 5% in the quarter and 9% year-to-date, driven by growth drivers like PLAVIX* and ABILIFY*, offset by international declines (-7% in Q2, -8% YTD) due to foreign exchange and generic competition.
• Profitability: Net earnings decreased 33% in the quarter and 10% year-to-date. The effective tax rate increased significantly to 23.1% (Q2) and 25.4% (YTD) compared to negative or low rates in 2005, due to the expiration of tax credits and the absence of 2005 tax benefits.
• Expenses: Research and development expenses increased 14% in both periods due to investments in late-stage compounds. Cost of products sold increased as a percentage of sales (32.2% in Q2) due to sales mix shifts and reclassifications.
• One-Time Items: The six-month 2006 results included a $200 million pre-tax gain on the sale of the DOVONEX* product asset. Conversely, 2005 results included significant litigation charges and insurance recoveries that are not present in the current period.

Outlook, Risks, and Management Commentary

• PLAVIX* Litigation Risk: The most significant risk is the pending patent litigation regarding PLAVIX* (the company's largest product, ~$3.8B annual sales). A proposed settlement with Apotex failed to receive required antitrust clearance. Apotex has terminated the settlement and is expected to launch a generic version shortly. Management states the impact cannot be reasonably estimated but warns that sustained generic competition would be material to sales, operations, and liquidity.
• Legal Investigations: The Department of Justice is conducting a criminal investigation regarding the proposed PLAVIX* settlement. The company is also subject to a Deferred Prosecution Agreement (DPA) regarding prior accounting practices.
• Product Pipeline: Recent approvals include SPRYCEL (CML treatment), BARACLUDE (hepatitis B), and ATRIPLA (HIV). ORENCIA (rheumatoid arthritis) was launched in the U.S. in February 2006.
• Liquidity: Management believes cash generated from operations and existing resources are sufficient to cover needs, excluding the potential material impact of PLAVIX* generic competition. The company maintains a strong credit rating (A1/A+).

Investor Verification Checklist

• PLAVIX* Generic Launch: Verify the timeline and market share impact of Apotex's generic clopidogrel launch following the failed settlement.
• DOVONEX* Gain: Confirm the $200 million gain on the sale of DOVONEX* is treated as a non-recurring item when analyzing core operating performance.
• Tax Rate Normalization: Assess the sustainability of the 2006 effective tax rate (~25%) compared to the anomalously low rates in 2005.
• DOJ Investigation: Monitor updates on the Department of Justice criminal investigation regarding the PLAVIX* settlement negotiations.
• Inventory Levels: Review the "months on hand" data for key products (e.g., CEFZIL, TEQUIN) to assess potential future write-downs or return accruals.